Literature DB >> 9069298

Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favoring preoperative treatment.

B Glimelius1, U Isacsson, B Jung, L Påhlman.   

Abstract

PURPOSE: This study explored the relationship between radiation dose and reduction in local recurrence rate after preoperative and postoperative radiotherapy in rectal cancer. METHODS AND MATERIALS: All randomized trials initiated prior to 1988 comparing preoperative and postoperative radiotherapy with surgery alone or with each other were included. Local failure rates were available in 5626 randomized patients. The linear quadratic formula was used to compensate for different radiotherapy schedules.
RESULTS: For preoperative radiotherapy, a clear dose-response relationship could be established. For postoperative radiotherapy, the range of doses was narrow, and a dose-response relationship could not be demonstrated. At similar doses, preoperative radiotherapy appeared to be more efficient in reducing local failure rate than postoperative. The only trial comparing preoperative with postoperative radiotherapy confirms this notion. A 15-20 Gy higher dose may be required postoperatively than preoperatively to reach similar efficacy. Neither approach alone significantly influences survival, although it is likely that a small survival benefit may be seen after preoperative radiotherapy.
CONCLUSIONS: The information from the entire randomized experience suggests that preoperative radiotherapy may be more dose efficient than postoperative radiotherapy.

Entities:  

Mesh:

Year:  1997        PMID: 9069298     DOI: 10.1016/s0360-3016(96)00510-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

Review 1.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 3.  Short-course versus long-course neoadjuvant radiotherapy for lower rectal cancer: a systematic review.

Authors:  M S Sajid; M R S Siddiqui; B Kianifard; M K Baig
Journal:  Ir J Med Sci       Date:  2009-06-30       Impact factor: 1.568

4.  Genomic predictor of complete response after chemoradiotherapy in rectal cancer.

Authors:  Gyoung Tae Noh; Nam Kyu Kim
Journal:  Ann Transl Med       Date:  2016-12

5.  Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer.

Authors:  Jin-hong Park; Jong Hoon Kim; Seung Do Ahn; Sang-wook Lee; Seong Soo Shin; Jin Cheon Kim; Chang Sik Yu; Hee Cheol Kim; Yoon-Koo Kang; Tae Won Kim; Heung Moon Chang; Min Hee Ryu; Eun Kyung Choi
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

6.  Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial.

Authors:  M Dahlberg; B Glimelius; L Påhlman
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

7.  Adjuvant and neoadjuvant treatment of resectable, locally advanced, rectal carcinoma with radiation therapy and chemotherapy.

Authors:  Roland B Hawkins
Journal:  Ochsner J       Date:  2002

8.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Prospective, randomized trial examining the role of gentamycin-containing collagen sponge in the reduction of postoperative morbidity in rectal cancer patients: early results and surprising outcome at 3-year follow-up.

Authors:  Marek P Nowacki; Andrzej Rutkowski; Janusz Oledzki; Maciej Chwaliński
Journal:  Int J Colorectal Dis       Date:  2004-09-15       Impact factor: 2.571

10.  Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial.

Authors:  Mostafa Abd Elwanis; Doaa W Maximous; Mohamed Ibrahim Elsayed; Nabiel N H Mikhail
Journal:  World J Surg Oncol       Date:  2009-06-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.